1283727-52-5

Upstream product

• 875-88-7 1-(2-phenylpropyl)hydrazine 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 1459-00-3 1-bromo-2-phenylpropane 
• 55-52-7 pheniprazine 
• 2114-39-8 (2-bromopropyl)-benzene 

Downstream Products

• 1283727-55-8 N-(3-chlorophenyl)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1283727-54-7 4-chloro-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1283727-53-6 1-(2-phenylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1338789-18-6 1-(2-phenylpropyl)-6-thioxo-1,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1338789-20-0 6-(methylthio)-1-(2-phenylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]-pyrimidin-4-one 
• 1338789-22-2 4-chloro-6-(methylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]-pyrimidine 
• 1338789-24-4 N-benzyl-6-(methylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1338789-25-5 N-(2-fluorobenzyl)-6-(methylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1338789-26-6 N-(4-fluorobenzyl)-6-(methylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1338789-27-7 N-(2-chlorobenzyl)-6-(methylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1338789-29-9 6-(methylthio)-N-phenyl-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1338789-31-3 N-(3-chlorophenyl)-6-(methylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1338789-34-6 (3-bromo-phenyl)-[6-methylsulfanyl-1-(2-phenyl-propyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 
• 1338789-11-9 N-benzyl-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells

Neuroblastoma (NB) represents the most common extracranial paediatric solid tumor for which no specific FDA-approved treatment is currently available. The tyrosine kinase c-Src has been reported to play an important role in the differentiation, cell-adhes

Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4- d ]pyrimidines active in hypoxic human leukemia Cells: A lead optimization study

A family of dual Src/Abl inhibitors characterized by a substituted pyrazolo[3,4-d]pyrimidine scaffold was previously reported by us and proved to be active against several tumor cell lines. Among these compounds, a promising antileukemia lead (1) has been recently identified, but, unfortunately, it suffers from substandard pharmaceutical properties. Accordingly, an approach for the optimization of the lead 1 is described in the present work. A series of more soluble pyrazolo[3,4-d]pyrimidine derivatives were rationally designed and proved to maintain the dual Src/Abl activity of the lead. Selected compounds showed an interesting activity profile against three different leukemic cells also in hypoxic conditions, which are usually characterized by imatinib-resistance. Finally, in vitro ADME properties (PAMPA permeation, water solubility, microsomal stability) for the most promising inhibitors were also evaluated, thus allowing the identification of a few optimized analogues of lead 1 as promising antileukemia agents.